Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335838 | 0.79 | HDAC8 (0.42) | SLC6A2SLC6A3HDAC8ALOX5APRECQL | |
| SCHEMBL3374322 | 0.77 | SLC6A2 (0.46) | SLC6A2SLC6A3ALOX5APSLC6A4RAB9A | |
| SCHEMBL3375694 | 0.77 | TDP1 (0.51) | SLC6A2SLC6A3ALOX5APSLC6A4RAB9A | |
| SCHEMBL14064674 | 0.73 | SMN1; SMN2 (0.52) | SLC6A2SLC6A3HDAC8ALOX5APSLC6A4 | |
| SCHEMBL4785130 | 0.73 | ADRB2 (0.37) | SLC6A2HDAC8ALOX5APRECQLKMO | |
| SCHEMBL13068613 | 0.70 | MEN1 (0.66) | SLC6A2SLC6A3SLC6A4KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL27666400 | 0.69 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4KMT2AMEN1 | |
| SCHEMBL29350890 | 0.69 | RECQL (0.43) | SLC6A2RECQLKMOKMT2AMEN1 | |
| SCHEMBL878425 | 0.69 | RECQL (0.43) | SLC6A2RECQLKMOKMT2AMEN1 | |
| SCHEMBL21591511 | 0.68 | RECQL (0.41) | SLC6A2HDAC8RECQLKMOKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2005027837-A2 | SUBSTITUTED SULFONAMIDES | MERCK & CO., INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1499306-A2 | BICYCLIC AMIDES | Merck & Co., Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1494997-A1 | SUBSTITUTED ARYL AMIDES | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087037-A1 | SUBSTITUTED ARYL AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | SLC6A2 1371/4885SLC6A3 2064/4885HDAC8 3601/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | SLC6A2 1525/4885SLC6A3 2303/4885HDAC8 2815/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | SLC6A2 1390/4885SLC6A3 2186/4885HDAC8 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.